Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
Status:
Terminated
Trial end date:
2016-06-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess overall survival of anti-tumor immunization using
HyperAcute®-Lung immunotherapy versus Docetaxel in patients with progressed or relapsed
non-small cell lung cancer (NSCLC) that have been previously treated.